Document Type
Article
Publication Date
September 2023
Patent Number
11766429
CPC
A61K 31/4439, A61K 31/14, A61K 31/13
Abstract
A method of treating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), otherwise known as COVID-19, infection by administering nicotinic receptor antagonists and/or PPAR-γ agonists is presented. A combination of mecamylamine, or an isomer thereof, and pioglitazone synergistically reduces replication of SARS-CoV-2 in virus-infected cells and also synergistically reduces inflammatory cytokines such as IL-6, IL-β, and TNFα, which have been associated with SARS-CoV-2 infection.
Application Number
17/446021
Recommended Citation
Sanberg, Paul Ronald; Brechot, Christian Bernard; Mohapatra, Shyam S.; and Mohapatra, Subhra, "Nicotinic receptor antagonists and pioglitazone as therapeutic agents for Covid-19" (2023). USF Patents. 1357.
https://digitalcommons.usf.edu/usf_patents/1357
Assignees
University of South Florida
Filing Date
08/26/2021
